NGHIÊN CỨU BIẾN ĐỔI SỐ LƯỢNG BẠCH CẦU TRUNG TÍNH TRONG MÁU NGOẠI VI Ở MỘT SỐ BỆNH GAN MẠN TÍNH DO NHIỄM VIRUS VIÊM GAN B

Abstract

Objective: Hepatitis B virus (HBV) infection is a global health concern, with the consequence of HBV-related hepatitis (HB), HBV-related cirrhosis (LCB), and hepatocellular carcinoma (HCCB). Among these, HCCB is commonly diagnosed at the late stage, and results in poor prognosis. Neutrophil count (NEU) plays a critical role in immune response but is also contributes to immunosuppression in carcinogenesis. This study aimed to evaluate the change of NEU across different HBV-related liver diseases. Methods: A cross-sectional descriptive study was conducted on 100 patients with HCCB, 25 patients with HB, 25 patients with LCB, and 50 healthy individuals (HC) at the 103 Military Hospital and the 108 Central Military Hospital from 05/2024 – 05/2025. Results: NEU number was reduced in patients with HB and LCB, but significantly elevated in those with HCCB (p = 0.0045). NEU counts were higher in the HCCB, compared to other non-HCCB populations (HC + HBH + HBC), p = 00251. NEU discriminated HCCB from above non-HCCB individuals with AUC = 0.6332 (p = 0.0011). Moreover, within the chronic HBV-related disease (HB + LCB + HCCB), the HCCB group showed significantly higher NEU, compared to the others (p < 0.0001). In the population of HB + LCB + HCCB, NEU distinguished HCCB from HB and LCB, with AUC = 0.9058 (p < 0.0001). At the optimal cut-off value of NEU > 4.510, the marker achieved the sensitivity of 90% and the specificity of 82% in distinguishing HCCB from HBH and HBC. Conclusion: NEU counts are decreased in HB and LCB but elevated in patients with HCCB. NEU demonstrates high diagnostic value in distinguishing HCCB from HB and LCB, making it a promising candidate biomarker for early HCCB screening in individuals with chronic HBV-related liver diseases.